glp 1 pharmacology Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Agonist-Induced Delayed Gastric Emptying

GLP-1 medications have revolutionized weight loss treatment by addressing the biological mechanisms that make weight loss difficult

Of the 14 PDPs available to the average beneficiary in 2025, 12 are national PDPs (available in all 34 PDP regions nationwide) (Appendix Table 1)

A rapid escalation is associated with low blood sugar levels and severe GI side effects such as severe abdominal pain, nausea, vomiting, and inflammation of the pancreas (pancreatitis)

People with type 2 diabetes often have risk factors for acute pancreatitis (e.g., gallstones or hypertriglyceridemia) (44)

DPP-4 inhibitors which increase levels of GLP-1, a hormone that helps reduce blood sugar levels have been approved for treatment of type 2 diabetes since 2006

COVID-19 vaccine demand waned, with Comirnatys sales halving, though COVID antiviral Paxlovid rebounded with some growth